The limited clinical success of anti-HGF/MET drugs can be attributed to the lack of predictive biomarkers that adequately select patients for treatment. We demonstrate here that quantitative digital imaging of formalin fixed paraffin embedded tissues stained by immunohistochemistry can be used to measure signals from weakly staining antibodies and provides new opportunities to develop assays for detection of MET receptor activity. To establish a biomarker panel of MET activation, we employed seven antibodies measuring protein expression in the HGF/MET pathway in 20 cases and up to 80 cores from 18 human cancer types. The antibodies bind to epitopes in the extra (EC)-and intracellular (IC) domains of MET (MET4  EC , SP44_MET  IC , D1C2_MET   IC   ) , to MET-pY1234/pY1235, a marker of MET kinase activation, as well as to HGF, pSFK or pMAPK. Expression of HGF was determined in tumour cells (T_HGF) as well as in stroma surrounding cancer (St_HGF). Remarkably, MET4
Introduction
Immunohistochemistry (IHC) is widely used clinically to aid with challenging diagnostic decisions that require formalin-fixed and paraffin embedded (FFPE) tissues. In the era of precision medicine, the ease associated with detecting proteins and phosphoproteins in single cancer cells via IHC is ideal for development of companion diagnostics needed to stratify patients for treatment with targeted therapies. However, technical problems diminishing the accuracy of quantifying the expression of drug targets by IHC hinder this biomarker development. The recent emergence of whole slide imaging and digital image analysis generates quantitative numerical data associated with protein expression in FFPE tissues [1, 2] . In theory, this approach could provide new opportunities for measuring the expression of drug targets in cancer tissues obtained from patients during routine medical care. However, the use of digital image analysis for biomarker development and companion diagnostics is still in its infancy [1] because it requires multidisciplinary interactions between pathologists, experts in image processing and software developers.
The MET receptor tyrosine kinase is a documented oncoprotein in human cancer (visual database available here: http://www.vai.org/met/). Our and other groups linked MET to epithelial-to-mesenchymal transition, invasion and metastasis in human cancer cells and in mouse models [3] . Germline activating mutations of MET cause hereditary papillary renal carcinoma and MET expression is associated with adverse outcome in practically all solid tumours [4, 5] . In addition, the human MET gene lies in an unstable genomic region on chromosome 7 that is prone to amplification [6, 7] . Hence, clonal expansion of cancer cells with multiple copies of the MET gene or with autocrine production of the MET ligand, Hepatocyte Growth Factor/Scatter Factor (HGF), can cause resistance to drugs that inhibit other receptor tyrosine kinases [8] . The key role of MET in oncogenesis and drug resistance provides a strong rationale for extensive drug development [9] . While most clinical trials with MET kinase inhibitors have not demonstrated an overall survival advantage, a subset of patients clearly experienced cancer control [10] .
The lack of appropriate companion diagnostics compromises the success of clinical trials with MET inhibitors [11] and the limited success may stem from inadequate selection of patients. Measuring the active MET kinase, ie, the drug target, relies on detection of protein phosphorylation, which constitutes an inherently unstable posttranslational modification. In addition, biomarker development is complicated by the sequestration of MET in signalling endosomes and shedding from the cell surface [12, 13] . Companion diagnostic assays for MET inhibitors employed MET FISH and MET IHC [14] . However, association of these measurements with activation of the MET kinase varies among cancer types [15] . Because of extensive post-translational regulation of MET protein expression, MET mRNA expression has not been explored as a biomarker of MET activation. Furthermore IHC to measure MET protein expression has not been stringently validated in FFPE tissues [16] . Collectively, the different mechanisms of MET kinase activities, ie, genomic mutations, binding of HGF and overexpression and/ or crosstalk with other cell surface receptors [3, 17] , have so far not resulted in the development of a uniform assay of MET receptor activation.
To analyze the activation of the MET pathway, we generated a tissue microarray (TMA) of 18 different cancer types. We employed seven antibodies that react with proteins in the MET pathway. SP44_MET
IC and D1C2_MET IC bind epitopes within the cytoplasmic C-terminus of MET and MET4 EC recognizes a motif in the MET receptor alpha-chain, which is extracellular [18] . We also utilized an antibody reactive with HGF. To determine the activation of cytoplasmic MET signalling pathways, we selected antibodies that bind phospho-MAPK and phospho-SRC-family kinases (SFK). Using quantitative digital imaging of slides stained by IHC, we generated a dataset consisting of 9139 individual measurements. The analysis of the data revealed that antibodies most predictive of MET activation differ amongst cancer types. This approach highlights the importance of cancer-type specific development of companion diagnostic assays for drugs against the active MET receptor kinase.
Materials and methods

Selection of cases and TMA construction
For TMA construction, 20 cases from 18 cancer types, which were randomly retrieved from the pathology archive, were displayed and confirmed by a subspecialty pathologist (Dataset S1 and Table S1 ). The MET genomic status was presumed to be identical to germline [19] . The core diameter was 0.6 mm except for sarcoma, melanoma, lymphoma, glioblastoma, head and neck cancer, and colon cancer, where it was 1 mm. Normal control blocks included kidney, tonsil, liver and colon. TMAs were constructed with the TMArrayer TM (Pathology Devices, Inc.).
Immunohistochemistry
Antibodies were obtained from Cell Signaling Technology (CST) or from other sources as indicated: METpTyr1234/pTyr1235 (clone D26), MET4 [18] , c-Met (clone SP44, Spring Bioscience), c-Met (clone D1C2), HGF (LifeSpan, BioSciences), Src-family-pTyr416, pErk1/2 (clone 137F5). Where needed, the specificity of antibodies was confirmed by western blotting before and after treatment with inhibitors (Figures S1A, S1B) [20] . The pSRC family-Tyr416 has not been optimized for IHC by the company (CST) and we therefore followed a published protocol [21] , which we also validated in a neoadjuvant bladder cancer study [22] . The HGF antibody has been characterized in the Vande Woude laboratory [23] and our protocol provides a staining pattern that is consistent with staining in mesenchymal cells. The specificity of the MET4 antibody was published in [18] . For each antibody, dilution, signal amplification and incubation conditions are listed in Table S2 . Staining was performed as described previously [24] . Secondary antibodies were purchased from CST. The tyramide signal amplification system (TSA) was purchased from Perkin Elmer and the polymer amplification system was obtained from VECTOR labs. The immunofluorescent staining was performed with the Opal multiplex immunofluorescent system (Perkin Elmer) and fluorescent staining with MET4 EC and SP44_MET IC was followed by IHC with the pMET antibody.
For every core, the percent coefficient of variation (%CV) for between-days (five slides) or within-day (three slides) assays was calculated by dividing the mean core intensity by the standard deviation. The total %CV was calculated by first averaging the squares of individual %CV values followed by taking the square root this value.
The IHC staining variability amongst cores within a case was compared to the variability across cases using F-statistics. Details of calculations are provided in the material.
Digital image acquisition, image processing and pathology annotation of TMA cores TMA slides were digitized on the high-resolution Leica SCN400NF whole-slide scanner and images were sequentially analyzed with the Tissue IA Optmiser (Leica) software installed on the Leica Digital Image Hub as described in [25] . Cancer and stromal areas were annotated by one of three pathologists and confirmed by second pathologist. The mean signal intensity (staining concentration) per unit area was calculated within annotated regions and exported for statistical analysis (Dataset S2).
Data acquisition and normalization
All statistical analyses were conducted in R v3.1.3 [26] . Plots were generated with the use of the following packages in R, beeswarm [27] , extrafont [28] , plyr [29] , RColorBrewer [30] , reshape2 [31] , scales [32] . TMA data were subjected to background intensity subtraction (lowest core intensity of individual slide) and log 2 transformation. Intensity values were normalized to the average signal intensities of kidney and tonsil control cores within respective slides. The final data represent the log 2 transformed fold change from control. As a second normalization method, control adjusted TMA data values (without background subtraction) were quantile normalized across slides and antibodies using limma [33] package in R.
Determination of distributions and correlation coefficients
Histogram density profiles of each antibody were constructed using ggplot2 [34] package in R. Unsupervised hierarchical clustering of pairwise Pearson's correlation matrix was calculated using hclust function based on Euclidean distance and complete linkage method. p-values of correlations generated for each antibody pair using data from all cancer types combined were adjusted using the stringent Bonferroni correction. p-values of pairwise correlations performed in cancer types individually were adjusted using the less stringent FDR correction [35] . Heatmaps were generated using heatmap.2() in gplots package [36] . The Dendrogram in Figure  S5A of the correlation matrix was generated using cluster package [37] . The Wilcoxon rank-sum test was used to determine the significance of the difference between of T_HGF and St_HGF signal intensities.
pMET z-score
In order to compare average levels of pMET expressions across cancer types, z-scores of pMET staining intensities were calculated as the difference of the cancer-type mean and grand mean, divided by the standard deviation of all samples, and then multiplied by the square root of number of cases in that particular cancer type. See supplementary material for details of the calculations.
Random forest classification
The expression of pMET was dichotomized at the 7th decile to classify cases as positive or negative. Levels of pMET were predicted by fitting a Random Forest model to all data with the following features: cancer-type plus all antibodies, or cancer-type plus either 1 of the antibodies (MET4, SP44_MET, D1C2_MET, T_HGF, St_HGF). Random forest classification analyses were conducted using the randomForest function [38] . 10-fold cross validation was performed and the area under the curve (AUC) of the receiver operating characteristic (ROC) curves was determined for each model using the ROCR package [39] . Variable importance for each model was calculated using the cforest function in the party package [40] [41] [42] .
Groups of five cancer-types (n 5 100 cases) were constructed for all possible cancer-type combinations 
Results
Differences in tissue staining between antibodies to the extra-and intracellular domain of MET
To identify potential differences in staining patterns of antibodies that react with the intracellular and extracellular domains of MET and with MET-pY1234/pY1235 (pMET), we stained tissue sections of renal cortex with a-pMET, SP44_MET IC (antibody against MET intracellular domain) and MET4
EC (antibody against MET extracellular domain) ( Figure 1A) . Surprisingly, we observed marked heterogeneity of staining in renal tubules. In particular, individual cells in collecting duct epithelium preferentially reacted either with MET4 EC or SP44_MET IC . Tubules that stained with a-pMET reacted with MET4
EC, but not with SP44_MET
IC
. These data highlight cell specific differences in availability of the MET4 EC and SP44_MET IC epitopes and suggest that antibodies against total MET protein might differ in their correlations with pMET levels. To take advantage of this result for development of companion diagnostics, we assembled a biomarker panel to investigate the relationship between MET phosphorylation, total MET protein expression, expression of HGF and activation of MET signalling pathways through SFK and MAPK.
Quantitative imaging of IHC with 7 antibodies in 18 cancer types
In order to test the MET-associated biomarker panel, we constructed a multi-cancer TMA consisting of 18 cancer types (lung adeno-and squamous carcinoma, mesothelioma, endometrium, ovary, breast, prostate, kidney clear cell, bladder, sarcoma, melanoma, pancreas, stomach, liver, lymphoma, glioblastoma, head and neck, and colon), 20 cases per cancer type and four cores per case ( Figure S3 , Dataset S1). In total, 1440 cores from 360 cases were displayed on seven glass slides. The average core loss after IHC was equally distributed across cancer types, such that 16-20 cases per cancer type provided data for statistical analysis. In addition, normal tissue cores were used for normalization and comparison of staining intensities across the seven slides.
Each TMA was stained with seven antibodies ( Figures  1B, S3 , Table S1 ). In order to overcome the problem of low sensitivity of measuring MET autophosphorylation at Y1234/Y1235 [43] , we combined polymer and tyramide amplification systems without compromising the dynamic range ( Figures S1C, S2B ). The improved amplification method applied to a-pMET IHC resulted in TMA cores above the limit of quantification in all 18 cancer types. Control rabbit and mouse antibodies were negative (data not shown). We acquired 1180-1230 measurements per antibody in areas of cancer and 726 measurements in the stroma ( Figure 1B ). For all antibodies and cancer types together, we obtained 9139 measurements (Dataset S2).
To compare the staining intensities from each antibody across seven slides, we subtracted the background staining and calculated the fold change relative to control cores in the same slide ( Figure  S4 ). The resulting distributions of control-adjusted, log 2 -transformed staining intensities were normally distributed, ie, 'bell-shaped' (S2A). The expression of pMET levels in 18 cancer types is shown in Figure 2A . Phospho-MET staining was highest in bladder cancer and lymphoma. In addition, outlier cases with high pMET levels were identified in lung adenocarcinoma, endometrial, prostate, stomach and liver cancer, and in melanoma. In order to assess the biological variability, we compared expression values between cases to those within a case. Between-case variability was significantly higher than within-case variability (F-test, adjusted p < 0.05) ( Figure 2B , Dataset S2), indicating that the within-tumour heterogeneity was less than the heterogeneity exhibited across cases. Furthermore, the a-pMET withinday coefficient of variation (%CV) 5 8.5% and the between-day %CV 5 26.7%, both acceptable for IHC assays ( Figure 2C ) [44] .
A switch from paracrine to autocrine HGF has been demonstrated during progression of AML and in the clonal selection of lung adenocarcinoma [8, 45] . However, the prevalence of autocrine HGF in other primary solid tumours is not known. To determine the relationship The boxplots depict the control adjusted log 2 expression of St_HGF and T_HGF in each cancer type. St_HGF expression could not be measured in cancer types that did not display sufficient regions of stroma with peritumoural mesenchymal cells (lymphoma, glioblastoma, sarcoma). A significant difference in expression between T_HGF and St_HGF is indicated by **p < 0.01, *p < 0.05.
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between HGF expression and MET activation, we profiled tumour HGF levels (T_HGF) in 1188 cores from 18 different cancer types. In addition, we measured HGF levels in the stroma adjacent to tumour (St_HGF) in 726 cores. The highest stromal HGF levels were detected in prostate and stomach cancer ( Figure 2D ). In addition, tumour and stromal HGF were correlated (r 5 0.56, p < 0.001) ( Figure 3A ).
Correlations between antibodies in the MET pathway and MET kinase activation
We reasoned that a better understanding of associations between antibodies that report the activation state of the MET pathway might allow for selection of surrogate biomarkers of MET activation. Thus, a correlation matrix was generated through IC antibodies with MET4 EC were lower (r 5 0.11, p 5 1 and r 5 0.11, p 5 1, respectively) ( Figures 3A, 3B, S5B ). The second group contains all the phospho-antibodies. The highest correlation in this group is observed between a-pSFK and a-pMET (r 5 0.56, p < 0.001). In contrast, the correlation between a-pMAPK and a-pMET is only r 5 0.20 (p 5 0.0053), suggesting greater pMET to pSFK than pMET to pMAPK signalling ( Figure 3A, C) .
MET4
EC demonstrated the highest correlation with apMET (r 5 0.47, p < 0.001), while correlation coefficients of SP44_MET
IC and D1C2_MET IC with apMET were lower (r 5 0.21 and r 5 0.08, respectively) ( Figure 3A, D) . The third group consists of MET4 EC , T_HGF and St_HGF. T_HGF and St_HGF are significantly correlated (r 5 0.56, p < 0.001) and, in addition, T_HGF is significantly correlated with MET4 EC ( Figure 3E , r 5 0.65, p < 0.001). Next, we performed an unsupervised hierarchical clustering analysis of pairwise correlation coefficients from 28 antibody pairs across the 18 cancer types (S6). Two major clusters were observed. The smaller cluster of five antibody pairs corresponds to pairs with the highest correlations in the correlation matrix in Figure 3A. To exclude a bias from the normalization method, we performed control-adjusted and quantile normalization method (S7) and observed similar correlation matrices (S8 and Figure 3A) . In summary, the main observation from the correlation matrix is the stronger correlation between MET4 EC and a-pMET compared to either SP44_MET IC or D1C2_MET IC and a-pMET. In addition, MET4 EC is strongly correlated (p < 0.001) with T_HGF and a-pSFK.
MET protein expression and MET phosphorylation in individual cancer types
Since MET can be activated through overexpression, we determined the relationship between MET protein expression and MET receptor phosphorylation in individual cancer types. MET Figure 3F ). Correlation coefficients r > 0.5 are twice as frequent for SP44_MET IC /pMET than for D1C2_MET IC /pMET ( Figure S9A ). Two cancer types (glioblastoma and endometrial) revealed high correlation coefficients (r > 0.4, FDR adjusted p < 0.1) for all three a-MET antibodies with a-pMET. The correlations with a-pMET in individual cancer types were not related to the z-score (normalized average level) of pMET expression (p > 0.1) ( Figure S10 ). Collectively, the results demonstrate that across cancer types, MET4 EC , which reacts with an epitope in the extracellular domain, reports pMET more faithfully than the antibodies that bind the cytoplasmic Cterminus of MET and that MET activation and protein levels are not related.
Next, we determined the correlations between HGF and pMET expression in individual cancer types. Correlations r 0.5 (FDR adjusted p < 0.1) between pMET and T_HGF were identified in four cancer types (head and neck, lymphoma, lung squamous and bladder carcinoma). While T_HGF (r 5 0.38) and St_HGF (r 5 0.29) were significantly correlated with pMET levels overall ( Figures 3A, S5B) , no correlation was observed with the z-scores of pMET levels (p > 0.1) ( Figure S10 ). The results suggest that in some cancer types, either autocrine or paracrine HGF expression may contribute to the activation state of MET.
Predictive models of MET activation
The ultimate goal of this multi-cancer investigation is to compare the accuracy of antibodies for predicting MET activation. We applied a random forest (RF) classification approach to determine which antibodies singly or in combination best predict MET receptor phosphorylation. The activation state of the MET receptor was set at the 70th percentile cutoff of signal intensities of a-pMET. We constructed ROC curves using 10-fold cross validation for RF models that consisted either of a combination of all a-MET and a-HGF antibodies or of single antibodies. The accuracy of predicting pMET levels was based on the area under curve (AUC) ( Figure 4A ). In addition, a variable importance measurement is provided by the RF model for the contribution of each antibody and of the cancer type to the prediction. As previously noted, data normalized by both background with control adjustment or by quantile normalization methods generated similar results ( Figure S11 ). The results from the RF prediction model underscore the important role of the cancer type in the prediction of MET activation status. To further examine the role of the cancer type in the prediction model, we combined data from five cancer types to increase the sample size. We also excluded D1C2_MET IC and St_HGF from further evaluation because of the low variable importance of D1C2_MET
IC and the absence of St_HGF in some cancer types. Figure 4B shows the combinations of five cancer types with the greatest AUC for MET4 EC , SP44_MET IC and T_HGF. These cancer type combinations were obtained from a total of 25,704 ROC curves for the three antibodies in all possible 5-cancer type combinations.
Since a different combination of cancer types is obtained for each of the antibodies, the ROC curves confirm the important role of the cancer type in the prediction of pMET activation by MET4 EC , SP44_MET IC and T_HGF.
Discussion
This study demonstrates for the first time that digital image analysis of IHC stained slides can be used as a general approach to improve the selection of ); (4) intratumoural HGF expression levels predict MET activation more accurately than HGF expression in the tumour microenvironment [8, 45] , and (5) the prediction of MET activation is cancer type-specific. Collectively, the data provide novel insights into the choice of antibodies to measure the active MET receptor kinase and are consistent with cancer-type specific mechanisms of MET activation.
The comparison of MET antibodies that react with epitopes in the intracellular and extracellular domain of the receptor was prompted by the surprising differences of staining patterns in renal tubules ( Figure 1A ). The nature of MET receptor proteins that preferentially react with MET4 EC versus SP44_MET IC or D1C2_MET IC is not known. MET4
EC binds to an epitope in the 25 kDa alpha-chain of MET [18] and not to the transmembrane 140 kDa MET receptor beta-chain that interacts with SP44-MET IC and D1C2_MET IC at its C-terminus. The MET C-terminal domain contains docking sites for multiple proteins that form a large signalling complex in response to MET kinase activation and autophosphorylation [47] . It is conceivable that this protein complex hinders the binding of SP44_MET IC and D1C2_MET IC to active MET, particularly after tissues are fixed by formalin treatment. The steric hindrance is also consistent with the weaker correlation of SP44_MET IC and D1C2_MET
IC with a-pMET. In addition, MET4 EC and a-pMET staining intensities correlate strongly with intratumoural HGF and with a-pSFK, suggesting that the heightened MET activation is associated with an HGF-MET-pSFK signalling axis ( Figures 3A, S12 ). Previous measurements of tissue and plasma HGF in clinical trials with AMG-102 utilized HGF-specific ELISA assays and did not distinguish between intraand extracellular HGF [48] . As confirmed by our prediction model, intratumoural HGF qualifies as a novel biomarker of MET activation status that might improve the prediction of pMET activation status.
There are limitations of this study that remain to be addressed. One is the true clinical predictive power of biomarkers in the MET pathway. While we have improved the reproducibility and sensitivity of detection of pMET through a combination of signal amplification and QI, the clinical significance of measuring pMET using this approach remains to be determined. It is also unclear whether pMET is sufficient as a treatment response biomarker and whether a-MET protein and a-HGF measurements are required to improve the prediction. Since phosphorylation is unstable and rapid fixation of biopsies is required to preserve the phosphoproteome [49] , it is a reasonable assumption that antibodies that are not dependent on phosphorylation will be needed to determine the MET activation status in clinical samples. An answer to these questions can be obtained in the future by analysis of tissues from clinical trials with MET inhibitors. Another limitation is the small sample size of individual cancer types. Based on the marked differences of biomarker expression among cancer types, expanding cohorts of individual cancer types will be necessary to obtain conclusive results for each of the cancer types included in the study. Our attempts to build a prediction model by using 5-cancer type combinations is the most detailed analysis that our sample size permitted and the prediction of MET activation by MET4 and T_HGF expression levels is consistent with the correlations between pMET and MET4 or T-HGF.
The results in our study explain conclusions by others demonstrating the lack of strong correlation between MET expression and response to MET inhibitory antibodies [50] [51] [52] [53] and highlight the importance of a cancer type specific development of companion diagnostics to MET inhibitory drugs.
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